相似文献
1
Sulfinpyrazone after myocardial infarction: no decision yet.
N Engl J Med. 1980 Dec 18;303(25):1476-7. doi: 10.1056/NEJM198012183032510.
2
The FDA's critique of the anturane reinfarction trial.
N Engl J Med. 1980 Dec 18;303(25):1488-92. doi: 10.1056/NEJM198012183032534.
3
The anturane reinfarction trial.
N Engl J Med. 1980 Jul 3;303(1):49.
4
The anturane reinfarction trial.
N Engl J Med. 1980 Jul 3;303(1):48.
5
The anturane reinfarction trial.
N Engl J Med. 1980 Jul 3;303(1):48.
6
[Sulfinpyrazone in the prevention of sudden cardiac death after myocardial infarct].
Med Clin (Barc). 1980 Jun 10;75(1):32-4.
7
FDA says no to anturane.
Science. 1980 Jun 6;208(4448):1130-2. doi: 10.1126/science.6990491.
8
Sulfinpyrazone after myocardial infarction.
N Engl J Med. 1978 Jun 1;298(22):1257-9. doi: 10.1056/NEJM197806012982212.
9
More on sulfinpyrazone after myocardial infarction.
N Engl J Med. 1982 Apr 22;306(16):988-9. doi: 10.1056/NEJM198204223061611.
10
[Sulfinpyrazone in the prevention of sudden death after myocardial infarction (author's transl)].
MMW Munch Med Wochenschr. 1980 Apr 4;122(14):517-24.
引用本文的文献
1
An overview of coronary artery disease-1981.
Cardiovasc Dis. 1981 Jun;8(2):159-164.
Zotero 插件